This article was sourced from the National Cancer Institute (NCI). This article will be updated automatically from NCI.

Lonza
MabPlex
ADC Bio
Broadpharm
 

Be a part of a community of ADC professionals and businesses. Share your expertise, discover new solutions, network with peers and grow your business. Become a member of the ADC Directory from the publishers of ADC Review. Join today!
Previous articleWhat are targeted therapies?
Next articlePEGS 2019: Using Economic Modelling In the ADC Manufacturing Supply Chain
ADC Review
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.